The U.S. Food and Drug Administration (FDA) made changes to the authorized use of the monoclonal antibodies bamlanivimab and etesevimab when they are administered together for the treatment of COVID-19.
The emergency use authorization (EUA) now authorizes the combination of bamlanivimab and etesevimab only in states, territories, and U.S. jurisdictions in which recent data shows the combined frequency of SARS-CoV-2 variants resistant to bamlanivimab and etesevimab administered together is less than or equal to 5%.
Currently, FDA has authorized the drug combination in 22 states.
The FDA has posted a list of states, territories, and U.S. jurisdictions in which bamlanivimab and etesevimab administered together are currently authorized, and a list of states, territories, and U.S. jurisdictions in which the combination of bamlanivimab and etesevimab is not currently authorized, and will periodically update both lists as new data and information becomes available.
The FDA issued the original EUA to Eli Lilly & Co.
